Media stories about Alliqua BioMedical (NASDAQ:ALQA) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alliqua BioMedical earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.0237480642377 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Stock in the Limelight: Alliqua BioMedical, Inc. (NASDAQ:ALQA … - FLBC News (flbcnews.com)
- Tale of the Ticker: Integra LifeSciences Holdings Corp (IART), Alliqua BioMedical Inc (ALQA) Moving on Volume - Evergreen Caller (evergreencaller.com)
- Investors Are Circling Alliqua BioMedical Inc (ALQA), What Do the Numbers Tell Us? - Sparta Review (spartareview.com)
- Alliqua BioMedical, Inc. (ALQA) is at $0.27 per share and RTI … - Stocks Gallery (stocksgallery.com)
- Alliqua BioMedical, Inc. (ALQA) Lowered to “Hold” at Zacks Investment Research (americanbankingnews.com)
Shares of Alliqua BioMedical (ALQA) traded down 2.222% on Monday, reaching $0.264. The company had a trading volume of 26,581 shares. The company’s 50-day moving average price is $0.35 and its 200 day moving average price is $0.44. The firm’s market capitalization is $13.23 million. Alliqua BioMedical has a 52 week low of $0.26 and a 52 week high of $1.11.
Alliqua BioMedical (NASDAQ:ALQA) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.05. The firm had revenue of $5.52 million during the quarter, compared to the consensus estimate of $5.01 million. Alliqua BioMedical had a negative return on equity of 107.24% and a negative net margin of 185.30%. The firm’s revenue was up 23.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.22) EPS. On average, analysts expect that Alliqua BioMedical will post ($0.44) EPS for the current year.
A number of equities research analysts have commented on ALQA shares. HC Wainwright reduced their price objective on Alliqua BioMedical from $2.50 to $1.50 and set a “buy” rating for the company in a research note on Tuesday, July 4th. ValuEngine cut Alliqua BioMedical from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research upgraded Alliqua BioMedical from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Alliqua BioMedical presently has a consensus rating of “Hold” and a consensus target price of $1.31.
TRADEMARK VIOLATION NOTICE: “Alliqua BioMedical (ALQA) Receiving Somewhat Favorable News Coverage, Accern Reports” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://stocknewstimes.com/2017/08/21/alliqua-biomedical-alqa-receiving-somewhat-favorable-news-coverage-accern-reports.html.
Alliqua BioMedical Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
